Lineage Cell Therapeutics, Inc. (LCTX) Ownership
LCTX ownership summary
as of October 18, 2026- Institutions
- 48.4% of shares outstanding
- Insiders
- 4.86% of shares outstanding
- Shares outstanding
- 252.9M
- Float
- 190.9M shares available to trade
- Short interest
- 19.08% 29.1M shares short
- Days to cover
- 20.03 short interest up 0.4% vs prior month
- Institutions 48.39%
- Insiders 4.86%
- Other investors 46.75%
LCTX insider transactions
latest 1| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-12 | Brian M Culley | Buy | $1.62 | 15,000 | $24,300 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
LCTX shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns LCTX
Institutional investors own 48.4% of Lineage Cell Therapeutics's shares and insiders 4.86%. Short interest is 19.08% of the float, or 20.03 days of average trading volume. The share count rose 195.2% since 2014.
Related: LCTX analyst forecast, LCTX key metrics. See the LCTX stock overview for the latest quote and news.
LCTX ownership FAQ
What percentage of Lineage Cell Therapeutics is owned by institutions?
Institutions hold 48.4% of Lineage Cell Therapeutics's shares outstanding; insiders hold 4.86%.
What is Lineage Cell Therapeutics's short interest?
29.1M shares of Lineage Cell Therapeutics were sold short, 19.08% of the float; at the average daily volume it would take 20.03 days to cover.
Are insiders buying or selling Lineage Cell Therapeutics?
Of the latest 1 reported insider transactions in Lineage Cell Therapeutics (since March 12, 2026), 1 were purchases and 0 were sales.
How many shares of Lineage Cell Therapeutics are outstanding?
Lineage Cell Therapeutics has 252.9M shares outstanding, of which 190.9M are in the public float.